Jefferies sees prescription rebound for Optinose’s Xhance

. After meeting with Optinose management, Jefferies analyst David Steinberg says that despite the recent setback, he continues to believe that Xhance will become a large product. Post adjustments to Xhance launch tactics, management believes they have made the proper changes and expect prescriptions to reaccelerate as summer ends, Steinberg tells investors in a research note. He points out that the company highlighted positive physician and patient feedback on the performance of the drug. The analyst keeps a Buy rating on Optinose with a $31 price target.
https://thefly.com/landingPageNews.php?id=2784563